Published in Can J Neurol Sci on November 01, 2010
Social Media Representation of Chronic Cerebrospinal Venous Insufficiency Intervention for Multiple Sclerosis. Int J MS Care (2016) 0.78
The Liberation Procedure Decision-Making Experience for People With Multiple Sclerosis. Glob Qual Nurs Res (2014) 0.75
Multiple sclerosis - a vascular etiology? Can J Neurol Sci (2010) 1.49
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology (2003) 2.13
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses (2006) 1.67
Natural, innate improvements in multiple sclerosis disability. Mult Scler (2012) 1.50
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain (2012) 1.03
Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods (2008) 1.03
Bilirubin possesses powerful immunomodulatory activity and suppresses experimental autoimmune encephalomyelitis. J Immunol (2008) 1.01
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open (2012) 1.00
Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler (2005) 0.99
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther (2012) 0.96
Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol (2006) 0.91
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler (2012) 0.91
Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care (2012) 0.90
Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
Pathological basis of diffusely abnormal white matter: insights from magnetic resonance imaging and histology. Mult Scler (2010) 0.89
Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis. J Interferon Cytokine Res (2011) 0.87
During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4. J Neuroimmunol (2006) 0.87
Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol (2003) 0.86
Escalating immunotherapy of multiple sclerosis. Ther Adv Neurol Disord (2008) 0.84
The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci (2008) 0.83
Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): comparing results of measurements in two different laboratories. J Immunol Methods (2012) 0.82
Terbutaline in myasthenia gravis: a pilot study. J Neurol Sci (2008) 0.82
Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology (2011) 0.81
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open (2014) 0.80
A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis. Clin Ther (2004) 0.80
Somatostatin preserved blood brain barrier against cytokine induced alterations: possible role in multiple sclerosis. Biochem Pharmacol (2013) 0.80
Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve (2013) 0.80
The measurement of antibodies binding to IFNbeta in MS patients treated with IFNbeta. Neurology (2003) 0.79
Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol (2014) 0.78
The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol (2007) 0.77
When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults? Mult Scler Int (2011) 0.77
A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res (2008) 0.77
Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler (2004) 0.77
Adult celiac disease with acetylcholine receptor antibody positive myasthenia gravis. World J Gastroenterol (2009) 0.76
Interferons in relapsing remitting multiple sclerosis. Lancet (2003) 0.76
DMDs are an essential issue but are they the only issue in MS treatment? Can J Neurol Sci (2013) 0.75
Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol (2004) 0.75
Where are we going with drugs to treat MS? Will cost continue to increase? Can J Neurol Sci (2010) 0.75
In myasthenia gravis, clinical and immunological improvement post-thymectomy segregate with results of in vitro antibody secretion by immunocytes. J Neurol Sci (2002) 0.75
Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf (2014) 0.75